Contract analysis

I. Question Presented Whether Calderwood & Harkness LLP should seek leave of court on behalf of Penterra Pharmaceuticals Corp. ("Penterra" or "Client") to file a sur-reply in response to the Opposition to Penterra's Motion for Summary Judgment and Reply in Support of Vantage's Cross-Motion for Summary Judgment (the "April 1 Brief"), filed by Vantage Medical Distribution, LLC ("Vantage"), through its counsel Hargrove,

II. Short Answer We should not seek leave to file a sur-reply. After a careful review of Vantage's 32-page April 1 Brief, I have concluded that it does not raise genuinely new arguments and does not introduce new evidence that was not fairly presented in Vantage's original Cross-Motion for Summary Judgment filed on February 25, 2022. The arguments advanced in the April 1 Brief are repackaged versions of positions tha

III. Procedural Background A. Briefing Schedule to Date The cross-motions for summary judgment have been fully briefed over the course of approximately two months. The relevant filings and dates are as follows: February 11, 2022 — Penterra's Motion for Summary Judgment. Penterra filed its Motion for Summary Judgment, supported by: (i) the Memorandum of Law in Support of Penterra's Motion for Summary Judgment (42 page

IV. Analysis of Vantage's April 1, 2022 Brief A. Overview of Vantage's Arguments Vantage's April 1 Brief is organized around three principal contentions, each of which closely tracks the arguments raised in Vantage's original Cross-Motion for Summary Judgment (February 25, 2022) and the underlying counterclaims filed by Vantage on May 14, 2021 (breach of contract, breach of the implied covenant of good faith and fair

V. Risk Assessment: Costs of Filing vs. Not Filing A. Risks of Seeking Leave to File a Sur-Reply Three principal risks attend a motion for leave to file a sur-reply in this case: Perception of weakness. A motion for leave to file a sur-reply may signal to Judge Costigan that we believe our existing briefing is incomplete or inadequate, or that Vantage's arguments have more force than we previously acknowledged. Given

VI. Alternative: Addressing Vantage's Points at Oral Argument Rather than seeking leave to file a sur-reply, I recommend that we direct our resources toward preparing comprehensive oral argument materials for Linda Osei's use at the May 6 hearing. This approach allows us to address any refined emphasis in Vantage's April 1 Brief in a more targeted and efficient manner, tailored to the court's actual questions and con

VII. Recommendation Based on the foregoing analysis, my recommendation is as follows: Do not seek leave to file a sur-reply. Vantage's April 1 filing repackages the same three arguments — (1) the Kapoor Email as "prior written consent" under Section 2.3; (2) course of dealing, waiver, and implied modification of Exhibit A; and (3) promissory estoppel based on detrimental reliance — that have already been fully addres

VIII. Appendix: Key Contract Provisions Referenced For convenience of reference, the following summarizes the key provisions of the Exclusive Distribution Agreement dated July 1, 2017 (the "EDA") between Penterra Pharmaceuticals Corp. ("Supplier") and Vantage Medical Distribution, LLC ("Distributor") that are central to the pending cross-motions:

Section 2.1 (Grant of Exclusive Territory). Grants Vantage the exclusive right to distribute Penterra's products within the Territory defined in Exhibit A, subject to the terms and conditions of the EDA. The exclusivity is limited to the geographic area specified in Exhibit A and does not extend to any territory not expressly listed therein.

Section 2.3 (Limitation on Distribution Outside Territory). Provides that the Distributor "shall not distribute, sell, or offer to sell the Products outside the Territory without the Supplier's prior written consent." This provision creates an affirmative prohibition on out-of-territory distribution and conditions any exception on the Supplier's "prior written consent" — a term that requires deliberate, documented au

Section 5.2 (Minimum Annual Purchase Commitment). Requires Vantage to purchase a minimum of $9.5 million per year of Penterra products at wholesale acquisition cost ("WAC"). This provision is relevant to the broader contractual framework and to Vantage's performance obligations within the defined Territory.

Section 13.1 (Amendments, Modifications, and Waivers). Provides: "No amendment, modification, or waiver of any provision of this Agreement shall be effective unless set forth in a written instrument signed by both parties." This provision is critical because it forecloses any claim that the EDA was modified by oral agreement, course of dealing, or unilateral conduct, and expressly requires a signed written instrument

Section 14.2 (Governing Law). Provides that the EDA shall be governed by and construed in accordance with the laws of the Commonwealth of Massachusetts, without regard to its conflicts of law principles.

Section 14.5 (Exclusive Jurisdiction). Provides that any dispute arising out of or relating to the EDA shall be brought exclusively in the courts of the Commonwealth of Massachusetts. This provision is the basis for the current action in the Business Litigation Session of the Suffolk County Superior Court.

Section 14.8 (Entire Agreement / Integration Clause). Provides: "This Agreement, including all Exhibits, constitutes the entire agreement between the parties with respect to the subject matter hereof and supersedes all prior negotiations, representations, or agreements relating thereto, whether written or oral." This integration clause establishes the EDA as the complete and exclusive statement of the parties' agreem